Reported about 15 hours ago
Vertex Pharmaceuticals (VRTX) reported quarterly earnings of $3.98 per share, which fell short of the Zacks Consensus Estimate of $3.99. This marks a decrease from $4.20 per share a year ago, resulting in an earnings surprise of -0.25%. However, the company’s revenues for the December 2024 quarter reached $2.91 billion, exceeding expectations by 5.16%. Despite the earnings miss, Vertex shares have increased by about 16.5% this year, suggesting positive market performance, although future outlook remains uncertain based on upcoming earnings estimates.
Source: YAHOO